Hut 8 Corp vs Oruka Therapeutics Inc. Common Stock — how do they compare? Hut 8 Corp trades at $73 (market cap $10.31B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Hut 8 Corp is the larger of the two by market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 12 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| HUT | ORKA | |
|---|---|---|
Market Cap | $10.31B | $5.18B |
Volume | 4,904,746 | 490,798 |
Sector | Financials | Health |
52-Week High | $133.02 | $113.08 |
52-Week Low | $33.76 | $26.19 |
Typical Hold Time | 12 Days | 0 Days |
Enterprise Value | $17.74B | $4.31B |
Signals from Pluang's Aura AI — not financial advice
HUT trades at $83.61, down 1.91% on the day, with a bearish technical signal from moving averages. The company shows strong revenue growth projections but faces significant profitability challenges with a -188.59% net income margin. Recent developments include securing a $1.07 billion credit facility and positive analyst coverage with 94% buy ratings and a $163.62 consensus price target.
While analyst sentiment remains overwhelmingly positive, HUT faces substantial execution risks with consecutive earnings misses and negative cash flow from operations. The stock offers significant upside potential based on analyst targets but requires careful monitoring of profitability improvements and AI infrastructure contract execution.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →